Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Abbott

Founders Wallace Calvin Abbott

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 9
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 8
Rounds per year 0.11
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 2
Key employees 1

Areas of investment

  • Health Care
  • Medical Device
  • Biotechnology
  • Predictive Analytics
  • Artificial Intelligence
Summary

In 1944 was created Abbott, which is appeared as Corporate Investor. The company was established in North America in United States. The main department of described Corporate Investor is located in the Illinois City.

Among the most popular portfolio startups of the fund, we may highlight SetPoint Medical, Respicardia, Ovalis. Among the most popular fund investment industries, there are Therapeutics, Life Science. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups.

The fund is constantly included in less than 2 investment rounds annually. This Abbott works on 0 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this Corporate Investor is 6 percentage points less often commits exit comparing to other organizations. The top amount of exits for fund were in 2009. The important activity for fund was in 2007. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Abbott, startups are often financed by Three Arch Partners, Polaris Partners, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, New Enterprise Associates, Latterell Venture Partners. In the next rounds fund is usually obtained by New Enterprise Associates, Polaris Partners, Lilly Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Abbott:
Typical Co-investors
Abbott is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Abbott:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Austin Rief Ventures -
California State Water Resources Control Board -
Dubai Cultiv8 Dubai, United Arab Emirates
Link VC Central, Central Region, Singapore
Phoenix Ventures -
Publics Venture Capital China, Guangdong, Guangzhou
Redwood Asset Management Canada, Ontario, Toronto
Three Gorges Capital Beijing, Beijing, China
Townsquare Media Connecticut, Greenwich, United States
VentureFund -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Bigfoot Biomedical

Artificial Intelligence
Big Data
Decision/Risk Analysis
Diabetes
Health Care
Medical Device
mHealth
Monitoring Equipment
Predictive Analytics
$55M13 Jan 2020 Milpitas, California, United States

SetPoint Medical

Biotechnology
Health Care
Medical Device
Neuroscience
$15M08 Sep 2015 Santa Clarita, California, United States

Respicardia

Health Care
Medical Device
Other Devices and Supplies
Therapeutic Devices
Therapeutics
$27M25 Aug 2010 Minnesota, United States

Ovalis

Biotechnology
Health Care
Medical Device
$6M13 Jan 2007 Mountain View, California, United States

Ovalis

Biotechnology
Health Care
Medical Device
$2M06 Nov 2005 Mountain View, California, United States

Hydra Biosciences

Biotechnology
Life Science
Medical
$18M12 Jan 2004 Cambridge, Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Abbott?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 9
Average round size 20M
Rounds per year 0.11
Peak activity year 2007
Lead investments 2
Follow on index 0.11
Exits 2
Group Appearance index 0.78

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Bigfoot Biomedical

Artificial Intelligence
Big Data
Decision/Risk Analysis
Diabetes
Health Care
Medical Device
mHealth
Monitoring Equipment
Predictive Analytics
$55M13 Jan 2020 Milpitas, California, United States

SetPoint Medical

Biotechnology
Health Care
Medical Device
Neuroscience
$15M08 Sep 2015 Santa Clarita, California, United States

Respicardia

Health Care
Medical Device
Other Devices and Supplies
Therapeutic Devices
Therapeutics
$27M25 Aug 2010 Minnesota, United States

Ovalis

Biotechnology
Health Care
Medical Device
$6M13 Jan 2007 Mountain View, California, United States

Ovalis

Biotechnology
Health Care
Medical Device
$2M06 Nov 2005 Mountain View, California, United States

Hydra Biosciences

Biotechnology
Life Science
Medical
$18M12 Jan 2004 Cambridge, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: